23 May Study Finds No Link Between Repatha® (evolocumab) and Cognitive Decline
Posted at 15:28h
in Author Interviews, Brigham & Women's - Harvard, Cognitive Issues, Heart Disease, JACC, Lipids
MedicalResearch.com Interview with:
[caption id="attachment_54285" align="alignleft" width="133"]
Dr. Giugliano[/caption]
Robert P. Giugliano, MD, SM
Senior Investigator, TIMI Study Group
Cardiovascular Medicine
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School Boston, MA
MedicalResearch.com: What is the background for this study?
Response: Some prior studies had suggested that lipid lowering therapies were associated with impaired cognition. We sought to explore this question in a prospectively designed substudy of the large FOURIER randomized, double-blind clinical trial utilizing patient self-surveys administered the end of the study to determine whether patients themselves noticed any changes in cognition over the duration of the trial.
The survey tool was a shortened version of the Everyday Cognition Questionnaire (see attached) that asks patients 23 questions that assess memory and executive function (including subdomains of planning, organization, and divided attention). The questions are in the format of "Compared to the beginning of the study, has there been any change in .....", and are graded as 1=better/no change, 2=questionable/occasionally worse, 3=consistently a little worse, 4=consistently much worse.
Dr. Filbey[/caption]
Francesca Filbey, PhD
Associate Provost and Professor of Cognition and Neuroscience
Bert Moore Chair
The University of Texas at Dallas
MedicalResearch.com: What is the background for this study?
Response: Studies have reported differences in how males and females respond to cannabis and how they develop problems related to cannabis use. We sought to determine whether craving may underlie this difference in male and female cannabis users.
Dr. Brooks[/caption]
Dr. Kelly Brooks PhD
Research Officer
QIMR Berghofer Medical Research Institute
MedicalResearch.com: What is the background for this study?
[caption id="attachment_54258" align="alignleft" width="200"]

Dr. Cavanaugh[/caption]
Alyson Cavanaugh, PT, PhD
Joint Doctoral Program in Epidemiology
University of California, San Diego/ San Diego State University
MedicalResearch.com: What is the background for this study?
Response: More than 700,000 total knee replacements are performed annually in the United States, but there is a racial disparity in outcomes after the surgery. If the knee replacement procedure is considered a highly effective treatment, why don't black women present with the same outcomes as whites?
Physical function when going into surgery has a large impact on the potential functional outcomes after surgery. Our hypothesis was that black women were presenting to surgery with poorer physical function, which was contributing to poorer functional outcomes after surgery.
Dr. Van der Pol[/caption]
Barbara Van Der Pol, PhD, MPH
President, American STD Association
President-Elect, International Society fo STD Research
Professor of Medicine & Public Health
Director, STD Diagnostics Lab
Director, UAB STD Clinical Research Organization
University of Alabama at Birmingham
Birmingham, AL 35294
MedicalResearch.com: What is the background for this study?
Response: For many decades, public health programs focused on control and prevention of sexually transmitted infections (STI) have relied on lab based tests that required a 1-day to 1-week wait for test results. Efforts to shorten the duration of infection lead to treating at the time of the clinic visit based on the association between certain clinical signs or symptoms and the likelihood of infection.
Unfortunately, more than ½ of infected persons do not have signs or symptoms so they receive no treatment until test results are available. Thus, a test that could be performed at the clinical site with a limited wait time would improve the accuracy of treatment and shorten the duration of infection. Such a strategy will hopefully reduce the number of return clinic visits, the possibility of transmission, and the potential for consequences of untreated infection such as infertility.
Dr. Tandon[/caption]
Pooja S. Tandon, MD, MPH
Center for Child Health, Behavior and Development
Seattle Children's Research Institute
MedicalResearch.com: What is the background for this study?
Response: Cell phone use is common among middle and high school students, yet we do not have an understanding of school cell phone policies and practices in the U.S. We conducted a survey of public schools serving grades 6-12. The survey sent to over 1,100 school principals, representing a national sample of schools across the U.S., asked questions about the presence of a cell phone policy for students and staff and restrictions on phone use. Additional questions addressed consequences of policy violation, the use of cell phones for curricular activities and principals’ attitudes toward cell phone policies.
Marco Taglietti, M.D.
President and Chief Executive Officer
SCYNEXIS Inc
Dr. Taglietti discusses SCYNEXIS’ announcement of positive results from its second Phase 3 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for vaginal yeast infection.
[caption id="attachment_54239" align="alignleft" width="200"]

Dr. Kaufman[/caption]
Gregory Kaufman, M.D.
Senior Vice President
Global Clinical and Medical Affairs
Specialty at Lupin
MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by trichomoniasis? How common is this infection?
Response: The Phase 3 trial evaluated the effectiveness and safety of a single oral dose of Solosec® (secnidazole) 2g oral granules for the treatment of trichomoniasis in adult women. Top-line results were positive and showed that Solosec was generally well-tolerated.
Trichomoniasis is the most common non-viral sexually transmitted infection (STI) in the U.S., and is caused by a protozoan parasite called Trichomonas vaginalis.